ContaCT

by Viz.AI  · Based in United States → — The leading AI care coordination platform for disease detection and workflow optimization.
Emergency Medicine Neurology Radiology
Website
Claim this tool
Is this the maker? Claim the company →

Subscription-based
Regulatory Status Disclosed

Overview

Viz.ai is a pioneering healthcare technology company that leverages artificial intelligence (AI) and machine learning to accelerate disease detection, streamline clinical workflows, and enhance care coordination. Founded in 2016, Viz.ai’s platform, Viz.ai One™, integrates real-time, multimodal clinical data with deep clinician engagement to help ensure patients receive timely and appropriate treatment.

The company gained its initial U.S. Food and Drug Administration (FDA) De Novo clearance in February 2018 for the Viz.AI Contact application (also known as Viz LVO Stroke Platform), a clinical decision support software designed to analyze CT results and notify providers of a potential stroke in their patients, specifically large vessel occlusions (LVOs). This marked a significant milestone as the first AI computer-aided triage software to receive FDA clearance.

Since then, Viz.ai has expanded its FDA-cleared algorithms to cover multiple therapeutic areas, including a De Novo approval in August 2023 for its Viz HCM module for hypertrophic cardiomyopathy (HCM) detection, and a 510(k) clearance in February 2024 for Viz ICH Plus for quantifying intracerebral hemorrhage. The platform is deployed in over 1,700 hospitals and health systems across the U.S. and Europe, aiming to reduce delays in patient care and improve outcomes for time-sensitive medical conditions.

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Key Features

  • AI-powered disease detection (LVO, ICH, HCM, PE, Aneurysm)
  • Real-time AI-powered alerts and notifications
  • Mobile application for specialists to view images and communicate
  • Secure, HIPAA-compliant group communication messaging
  • Integration with PACS and EHR systems
  • High-fidelity 3D web and mobile image viewer
  • Automated chart summarization
  • Guideline-based recommendations
  • Workflow optimization for acute care settings
  • Automated documentation and billing code suggestions (Viz Assist)

Use Cases

  • Accelerating stroke diagnosis and treatment pathways
  • Improving care coordination for neurovascular diseases
  • Early detection and management of hypertrophic cardiomyopathy
  • Quantifying intracerebral hemorrhage for treatment decisions
  • Optimizing radiology workflows and prioritization of critical findings
  • Facilitating real-time communication among multidisciplinary care teams

Details

Category Neurology AI, Radiology & Imaging AI
Pricing Subscription-based
  • Subscription-based; pricing varies significantly based on organization size, features, and implementation scope; often tiered for different types of stroke centers
DeploymentCloud-based, integrates with existing hospital IT infrastructure (PACS, EHR).
Compliance
BAA AvailableUnknown AI-estimated
HIPAA CompliantUnknown AI-estimated
FDA Status 1 AI-estimated

Viz.AI Contact application (LVO Stroke Platform) received De Novo clearance in February 2018 for stroke detection. Viz HCM module received De Novo approval in August 2023 for hypertrophic cardiomyopathy detection. Viz ICH Plus received 510(k) clearance in February 2024 for quantifying intracerebral hemorrhage.
Integrations
EHR Not specified
Specialties Emergency Medicine, Neurology, Radiology

Ratings & Reviews

No reviews yet. Be the first to review this tool!

Rate ContaCT

Clinical Value
Ease of Use
Integration
Support & Docs
Value for Money

Press & Coverage

DAIC
FDA Clears First AI-Powered Clinical Decision Support Software for Stroke
In February 2018, the FDA granted marketing clearance for Viz.AI's ContaCT application, the first AI-based clinical decision support solution for stroke in the U.S. This software analyzes CT results to notify providers of potential strokes, aiming to decrease time to treatment.
2018-02
FDA
FDA permits marketing of clinical decision support software for alerting providers of a potential stroke in patients
The FDA announced marketing authorization for the Viz.AI ContaCT application, a clinical decision support software that uses AI to analyze CT images for stroke indicators and alert neurovascular specialists. This aims to involve specialists sooner in the treatment process.
2018-02
Healthcare Dive
FDA OKs marketing of AI-enabled stroke alert for providers - Healthcare Dive
The FDA cleared Viz.AI's ContaCT application through the De Novo premarket review process, establishing a new regulatory classification for similar computer-aided triage software. The software analyzes CT brain scans to alert clinicians of potential stroke risks.
2018-02
Business Wire
Viz.ai Expands into Neurodegenerative Disease with Cortechs.ai Collaboration
Viz.ai announced a collaboration with Cortechs.ai to integrate NeuroQuant and NeuroQuant MS into the Viz.ai platform, expanding into neurodegenerative disease with a focus on multiple sclerosis. This partnership aims to enhance quantitative neuroimaging access for hospitals.
2026-07
Viz.ai
Viz.ai Launches Viz Agent Studio Enabling Health Systems to Build and Scale Their Own AI Care Pathways
Viz.ai launched Viz Agent Studio, a new capability within its Viz Oneu00ae Platform, allowing health systems to create and scale their own AI Care Pathways using natural language. This aims to improve adherence to clinical guidelines and patient outcomes.
2026-03
Viz.ai
New Study Highlights Positive Impact of Viz.ai on Enhancing Post-Stroke Patient Care
A clinical study published in The Neurohospitalist highlighted the positive impact of Viz Connect on post-stroke patient care, demonstrating improvements in cardiac monitoring utilization, care efficiency, and patient satisfaction.
2025-02
Stroke: Vascular and Interventional Neurology
Abstract 152: The diagnostic performance of Vizu2010ai and RAPID artificial intelligence algorithms for the detection of large vessel occlusions: A systematic review and Metau2010analysis
A systematic review and meta-analysis evaluated the diagnostic performance of Viz.ai and RAPID software for large vessel occlusion (LVO) detection in acute ischemic stroke. The study concluded that both software demonstrate high diagnostic accuracy, with Viz.ai showing slightly higher specificity.
2025-01
Viz.ai
Viz.ai Closes 2025 with Record Scale and Patient Impact, Achieving Profitability in Its Healthcare Business while Accelerating Life Sciences Growth
Viz.ai announced a milestone year in 2025, marked by significant growth in its provider network, profitability in its healthcare business, and expansion of its life sciences partnerships. The company's platform is used in nearly 2,000 hospitals.
2026-01

Videos

Product demos, reviews, and walkthroughs for ContaCT.

View all on YouTube

Frequently Asked Questions

ContaCT is designed to integrate seamlessly with various EHR systems, often leveraging standards like HL7 FHIR for data exchange. It aims to enhance workflows by providing real-time alerts, reminders for screenings, treatment protocols, and tailored recommendations directly within the physician's existing interface, improving efficiency and reducing errors.
ContaCT prioritizes patient data privacy by implementing robust security protocols, including encryption for data in transit and at rest, and role-based access controls. It is designed to be HIPAA compliant, often requiring Business Associate Agreements (BAAs) with healthcare providers to ensure protected health information (PHI) is handled securely.
Limitations can include alert fatigue, potential for over-reliance, and the need for up-to-date knowledge bases. Physicians should critically evaluate recommendations, understanding that CDS tools are meant to support, not replace, clinical judgment, and verify the evidence base behind the suggestions.
Alternatives range from other comprehensive CDS platforms like DynaMed to more specialized tools, or even integrated features within advanced EHRs. Key factors for evaluation include integration capabilities, the breadth and depth of the knowledge base, user interface, customization options, and vendor support.
Pricing models for CDS systems can vary, often including subscription-based fees per user or per practice, with potential additional costs for implementation and customization. Cost-effectiveness can be evaluated by considering potential reductions in medical errors, improved patient outcomes, enhanced efficiency, and compliance with quality metrics.
Implementation typically involves integration with existing IT infrastructure, data mapping, and customization to fit specific clinical guidelines and workflows. Comprehensive training for clinical staff is usually provided, along with ongoing technical support and regular updates to the system's knowledge base and features.

Compare ContaCT

VS
ContaCT vs SIS System
Clinical Decision Support & Reference Adjacent · 65/100
ContaCT is an AI-powered platform focused on accelerating the detection and care coordination for acute conditions such as stroke, utilizing real-time alerts and communication for various specialties. In…
VS
ContaCT vs HealthPNX
Clinical Decision Support & Reference Adjacent · 60/100
ContaCT is a broader AI-powered care coordination platform designed for detecting multiple conditions like stroke, PE, and aneurysms, emphasizing real-time alerts and communication across care teams. In contrast,…
VS
Viz CTP vs ContaCT
Clinical Decision Support & Reference Direct · 95/100
Viz CTP and ContaCT are highly comparable, both being AI-powered platforms from Viz.ai for disease detection and care coordination. Viz CTP appears to offer a more specialized focus…
VS
Viz SDH vs ContaCT
Clinical Decision Support & Reference Direct · 85/100
Viz SDH is an AI-powered tool specifically designed for the detection and management of subdural hemorrhage, offering detailed quantification and real-time alerts to neuro specialists. ContaCT, also from…

Related Tools

Cercare Medical Oncology Virtual Expert
Cercare Medical
Neurology AI
Cercare Medical's Oncology Virtual Expert is an AI-powered brain tumor segmentation module that provides fast, consistent, and semi-automated tumor analysis from standard MRI data, designed for on-premise deployment within existing clinical radiology workflows.
CoLumbo C-Spine
Smart Soft Healthcare AD
Clinical Decision Support & Reference
CoLumbo C-Spine is an AI-powered software that processes and analyzes cervical spine MRI exams, assisting clinicians in diagnosis and assessment.
MeRT System
Wave Neuroscience
Mental & Behavioral Health AI
MeRT (Magnetic e-Resonance Therapy) is an advanced, personalized form of TMS that uses your own brainwave data to guide treatment. It's a non-invasive, drug-free option designed to help the brain communicate more efficiently so symptoms of conditions like depression, anxiety, PTSD, TBI, autism, and more can improve.
Paid
Brainomix 360 Hyperdensity
Brainomix Limited
Neurology AI
Brainomix 360 Hyperdensity is an AI-powered neuroimaging software tool that detects and quantifies brain hyperdensities on CT scans, forming a crucial part of the Brainomix 360 Stroke platform for rapid and accurate stroke assessment.
SOMNUM
HoneyNaps
Clinical Decision Support & Reference
SOMNUM is an AI-enabled medical software tool by Honeynaps Co., Ltd. that provides comprehensive sleep analysis to aid in the diagnosis and management of sleep disorders.
DETECT-ME/CFS project
DETECT-ME/CFS project (ME/CFS Research Foundation)
Clinical Decision Support & Reference
The DETECT-ME/CFS project is developing an AI-supported clinical decision support system to improve the rapid and reliable diagnosis of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.

See all Neurology AI tools →

More from Viz.ai

Viz AAA
Viz.ai
Cardiology AI
Viz AAA is the first FDA-cleared AI-powered solution by Viz.ai for the detection and triage of suspected Abdominal Aortic Aneurysm (AAA) from CT angiography scans, designed to accelerate diagnosis and care coordination.
Subscription model
Viz ANEURYSM
Viz.ai
Neurology AI
Viz ANEURYSM is an FDA-cleared AI-powered solution by Viz.ai that auto-detects suspected cerebral aneurysms in CT angiograms (CTAs), streamlining neurovascular care coordination and facilitating timely patient management.
Contact for pricing
Viz CTP
Viz.ai
Clinical Decision Support & Reference
Viz.ai is a pioneer in AI-powered disease detection and intelligent care coordination, leveraging over 50 FDA-cleared algorithms to analyze medical imaging and streamline clinical workflows for faster diagnosis and treatment.
Subscription model
Viz HCM
Viz.ai
Cardiology AI
Viz HCM is an FDA-cleared AI tool by Viz.ai that uses real-time ECG analysis to detect suspected Hypertrophic Cardiomyopathy (HCM) and coordinate cardiac care, significantly reducing diagnosis time.
Subscription-based

View company profile →

Suggest an Edit → | Last Verified: 2026-04-19 | First Added: 2026-04-19

Investors who backed ContaCT

Funded through the company that built this tool.

Scale Venture Partners
VC T3
Foster City, United States
$5M-$25M
Scale Venture Partners is a Foster City-based growth-stage software firm investing primarily in B2B SaaS, with a long track record of leading…
AI/ML in Healthcare Care Delivery / Tech-Enabled Services
AI Tool Finder
AI-powered search. Results may not be comprehensive.